This article is more than 5 years old. Information may no longer be current.

ACC.18 late-breaking clinical trials announced

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The American College of Cardiology announced the lineup of late-breaking clinical trials scheduled for presentation at its 2018 Scientific Session, including 21 late-breaking clinical trials and 17 featured clinical research trials.

Perhaps the most eagerly awaited study is ODYSSEY Outcomes, a trial to determine whether the PCSK9 inhibitor alirocumab (Praluent, Sanofi/Regeneron) can prevent CV events in high-risk patients when added to statin therapy.

The ACC Scientific Session will be held March 10-12 in Orlando, Florida.

According to a press release from the ACC, some of the other studies included in the five late-breaking clinical trial sessions will include:

• VEST, in which researchers studied the efficacy of a wearable cardioverter defibrillator (LifeVest, Zoll) after MI.

• PHARMCLO, which evaluates a pharmacogenomic approach to the selection of antiplatelet therapy in ACS.

• ARTEMIS, which studied the impact of patient copayment reduction on continued P2Y12 inhibitor use and clinical outcomes after MI.

• TREAT, designed to explore the safety and efficacy of ticagrelor (Brilinta, AstraZeneca) compared with clopidogrel in patients with ST-segment elevation ACS treated with thrombolysis.

• MANAGE, examining the effect of dabigatran (Pradaxa, Boehringer Ingelheim) in patients suffering myocardial injury after noncardiac surgery.

• SECURE-PCI, a trial of loading doses of atorvastatin vs. placebo in patients with ACS and planned revascularization.

• Long-term outcomes of patients who underwent mechanical circulatory support therapy in the MOMENTUM 3 trial.

• CARES, a study of the CV safety of febuxostat (Uloric, Takeda) and allopurinol in patients with gout and CV comorbidities.

• A new diabetes-related analysis from the CANTOS trial of the anti-inflammatory therapy canakinumab (Novartis).

• TRIUMPH, a pragmatic trial of a low-dose triple-combination BP-lowering pill for initial treatment of hypertension.

• POISE, which will feature 1-year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery.

• STOP-PAD, a study in patients with CLI to evaluate the safety and efficacy of hSDF-1 plasmid (JVS-100) after open or endovascular revascularization to enhance wound healing.

• A study of device closure vs. medical therapy for secondary prevention in patients with cryptogenic stroke and high-risk patent foramen ovale.

Cardiology Today and Cardiology Today’s Intervention will report live from the sessions. Visit Healio.com/Cardiology during the sessions for breaking news, videos, perspective from experts in the field on major results and announcements, and more.